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Abstract 
Background. Aerobic treadmill exercise (T-EX) therapy has been shown to benefit 
walking and cardiorespiratory fitness in stroke survivors with chronic gait impairment 
even long after their stroke. The response to T-EX, however, varies between 
individuals. Objective. The purpose of this post-hoc analysis of two randomized 
controlled T-EX trials was to identify predictors for therapy response. Methods. Fifty-
two subjects received T-EX for 3 (Germany trial) or 6 (USA trial) months. 
Improvements in over-ground walking velocity (10-m/6-min walk) and in fitness as 
measured by peak exercise VO2 were indicators of therapy response. Lesion location 
and volume were measured on T1-weighted magnetic resonance scans. Results. T-
EX significantly improved gait and fitness with gains in 10-m walk tests ranging 
between +113% and -25% and peak VO2 between -12% and 88%. Baseline walking 
impairments or fitness deficits were not predictive of therapy response. 10-m walk 
velocity improved more in subjects with subcortical than with cortical lesions and in 
patients with smaller lesions. Improvements in 6-min walk velocity were greater in 
subjects with more recent strokes and left-sided lesions. No variable other then 
training intensity that was different between trials, predicted fitness gains. 
Conclusions. Despite proving overall effectiveness the response to T-EX varies 
markedly between individuals. While intensity of aerobic training seems to be an 
important predictor of gains in cardiovascular fitness, lesion size and localization as 
well as the time intervals between stroke onset and therapy delivery likely affect 
therapy response in walking parameters. These findings may be used to guide timing 
of training and to identify subgroups of patients for whom training modalities could be 
optimized. 
Key Words: stroke; lesion; gait; rehabilitation; aerobic treadmill exercise 
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Introduction 
Impaired gait after hemiparetic stroke contributes strongly to overall disability. 
Aerobic treadmill exercise (T-EX) has been successfully used to re-train gait and 
improve cardiorespiratory fitness at the same time thereby reducing the disability 
related to immobility. Several randomized controlled trials have demonstrated 
benefits on various outcome parameters in patients with chronic gait impairments 1-4. 
While group effects are significant, the individual response to T-EX is variable. The 
reasons of this variability are not known. Identifying predictors of therapy-related 
benefits will serve to select and adjust the intervention to the individual patient. 
For other rehabilitative treatments predictive parameters have been reported. 
Using functional magnetic resonance imaging 5-6, transcranial magnetic stimulation 7-8 
or positron emission tomography 9  it was shown that different brain areas undergo 
lasting changes after stroke and after rehabilitative interventions. These changes in 
brain activation are associated with the degree to which motor function recovers. 
Cramer and co-workers 10 suggested that lower baseline motor cortex activation 
predicts higher therapeutic benefit. Given that brain activation during hemiparetic 
movement depends on location and size of the brain lesion 6, it is conceivable that 
lesion geometry has prognostic value. Lesion geometry indeed explains part of the 
variability of acute deficits after stroke and of functional outcomes at three months 11-
15
. However, some studies have failed to show such relationships 10, 16.  
Age was also identified as a predictor of functional outcome in previous 
studies 17-18. This may be explained by higher frequency of co-morbidity, stroke-
related complications 14 and limited plasticity of the aging brain 19. The objective here 
was to investigate the value of clinical, demographic and lesion-related variables to 
predict the benefit provided by T-EX in chronically disabled stroke survivors. 
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Materials & Methods 
Subjects 
This post-hoc analysis combines data from two randomized controlled trials that were 
conducted by the same collaborative group of researchers. Six months of aerobic 
treadmill exercise (T-EX) were compared with stretching exercises of equal duration 
in Baltimore,MD,USA 2, 20. The second trial, conducted in Stuttgart, Germany, 
compared 3 months of T-EX to conventional care. Here, we analyzed the fifty-two 
subjects from the T-EX groups of both trials for whom structural imaging data were 
available (Table 1).  
Subjects in both studies have suffered a first time ever, ischemic stroke at least 6 
months prior to enrollment. Exclusion criteria were heart failure, unstable angina, 
peripheral arterial occlusive disease, aphasia, dementia, untreated major depression, 
clinical and/or neuroimaging signs of stroke-independent neurological diseases (e.g. 
Parkinsonian syndromes), patients already performing aerobic exercise training for > 
20 minutes/d and > 1d/week and other medical conditions precluding participation in 
exercise (for details see 21). The trials were approved by institutional review boards of 
the University of Maryland and the Johns Hopkins University (USA trial) and the 
Ethics Committee of the University of Tübingen, Germany (Germany trial). All 
participants provided written informed consent. 
Assessments of gait function and cardiovascular fitness 
Subjects were enrolled when capable of completing ≥3 consecutive minutes of 
treadmill walking at ≥ 0.1 m/sec without personal or body weight support (use of hand 
rails was allowed) and without signs of myocardial ischemia or other 
contraindications to training. During a peak-effort treadmill exercise test with open 
circuit spiroergometry, cardiovascular fitness was determined by measuring VO2  
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((ml/kg bodyweight)/min) according to the standards of the American Heart 
Association 21-22 under continuous monitoring of vital signs and ECG. For peak VO2 
testing a modified Balke protocol (increase of treadmill incline every two minutes with 
constant speed) was applied – a procedure to assess cardiovascular fitness in stroke 
patients with a reliability of repeated measurements of heart rate, systolic blood 
pressure, oxygen consumption (VO2 (l/min)), VO2 (ml/(kg*min)), respiratory exchange 
ratio, rate-pressure product, and oxygen pulse 23. Locomotor impairments were 
assessed by two widely used and well characterized tests 24-25. The time required to 
walk 10 meters at fastest and comfortable pace was used to assess the ability to 
walk short distances typical for the home environment. The distance walked during 6-
min was added to evaluate sustained walking capacity. To render both tests 
comparable to each other and to published reference data, the mean velocity was 
calculated for both walking tests and was used in further analyses. Functional 
assessments were conducted before and after the training period. 
Training 
The T-EX training goal was three 40-minute exercise sessions per week at an 
aerobic intensity of 60% in the USA trial and 80% of heart rate reserve (HRR) in the 
Germany trial. Duration and intensity started low (10-20 min, 40-50% HRR) and 
increased approximately 5 min and 5% HRR. To reach the training intensity target, 
treadmill velocity was increased by 0.05 m/sec every 1-2 weeks as tolerated. In the 
USA trial training was conducted for 6 months, in the Germany trial for 3 months. 
MRI data acqusition 
In the USA trial, structural MRI data were collected using a 1.5 T Philips 
scanner (Philips, Eindhoven, Netherlands) within two weeks of the start and end of 
the training. In the Germany trial, MRI data were acquired at a 3T scanner (Vision, 
  		
	
Siemens, Erlangen, Germany). T1-weighted (3D-MPRAGE sequence, resolution 1 
mm3) images covering the entire brain were acquired to determine lesion location 
and size. Functional MRI data collected in the USA trial are reported elsewhere2. 
Image analysis 
Lesion location was first determined by visual inspection performed by two 
raters independently (ARL and BH for USA trial; JML and CG for Germany trial). 
Lesions were stratified into cortical/subcortical white matter with or without basal 
ganglia involvement, further referenced as “cortical” lesions, and “subcortical” lesions. 
The latter were defined as lesions restricted to the region medial to the insula and 
inferior to the corpus callosum. Brainstem lesions were regarded as “subcortical”. 
To determine lesion volume, binary lesion masks were produced by manually 
segmenting the lesion area on all consecutive sections displaying the lesion. Lesion 
area was defined on T1 images as all voxels isointense to CSF plus hypodense 
voxels at the boundary of the lesion core. Manual segmentation was performed using 
MRIcro26. All voxels defining the lesion (1voxel=1mm3) were counted using a Matlab 
script (Mathworks Inc, Natick, MA, USA). 
 
Statistical analysis 
The changes in functional assessments (10-m walk test, 6-min walk test and peak 
VO2) were expressed as absolute and relative change as related to baseline 
performance. In addition to absolute change, relative changes were analyzed 
because we expected patients with higher impairment to show less absolute 
improvement as compared to patients with less deficit. General linear models were 
used to assess the effects of age, gender, stroke onset-to therapy onset interval, 
lesion volume, side and location (cortical, subcortical) on the dependent variables. 
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Dependent variables were either baseline performance or change of performance 
(absolute or relative to baseline) in fitness and walking tests. In the models 
investigating change variables, the baseline value of the respective change variable 
was added as a covariate. Independent variables were entered into the model in a 
stepwise fashion using a criterion of p<0.25 and then removed if p>0.05. After 
identifying significant predictors, 2-way interactions between them were first added to 
the model and then removed if their effect was insignificant (p>0.05). The efficacy of 
treadmill exercise to improve fitness and gait was tested using repeated measures 
ANOVA models, one for each outcome parameter. All data are expressed as mean ± 
SEM. 
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Results 
Baseline functional impairment 
The patients enrolled in Germany walked faster at their self-selected pace at baseline 
and had better cardiovascular fitness (Table 2) compared to those in the USA trial. 
Over-ground walking velocity as measured in the 6-min walk test and the velocity in 
10-m walk test was slower in females, in older participants, in those with larger 
lesions (for 10-m walk test fastest pace) and higher baseline NIHSS (Table 3). For 
gait velocity derived from the 6-min walk test, we found a higher negative correlation 
with NIHSS among subjects in the Germany than in the USA trial. Low 
cardiorespiratory fitness was predicted by female gender, right-sided lesion and high 
(indicating greater impairment) NIHSS. No other interactions between trial and other 
independent variables were significant. 
 
Exercise-related functional gains 
Treadmill training lead to increased gait velocity as measured by 10-m walk test 
(fastest pace 0.85±0.06 → 0.96±0.06 m/sec, p<0.0001; comfortable pace 0.67±0.05 
→ 0.75±0.05, p=0.0006) and increased gait velocity as measured during the 6-min 
walk (0.70±0.05 → 0.84±0.06, p<0.0001). Treadmill exercise also improved 
cardiorespiratory fitness (peak VO2 17.9±0.94 → 21.7±1.18 ml/kg/min, p<0.0001). 
There were no significant correlations between gains in fitness and velocity (p>0.5 for 
all gait tests). Absolute and relative gains in these outcome parameters are 
presented in Table 2.  
Predictors of exercise-related functional gains 
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Relative improvements in 10-m walk velocities were higher in subjects with smaller 
lesions (Table 3). Relative gains in 6-min walk velocity were higher in subjects with 
more recent stroke events. Relative improvement in fitness (peak VO2) was higher in 
Germany than in USA subjects (Table 3). 
Absolute changes in walking or fitness were not predicted by baseline walking 
velocities or fitness. Absolute improvement in gait velocity measured during the 10-m 
walk test (fastest or comfortable pace) was greater in subjects with subcortical than 
with cortical lesions (Table 4). While improvements in patients with subcortical 
lesions were significant for both comfortable and fastest walking velocity (fastest 
pace: gain 0.13±0.02 m/s, p<0.0001; comfortable pace: 0.09±0.02 m/s, p<0.0001), 
gains in subjects with cortical lesions failed to reach significance (fastest pace: gain 
0.05±0.03 m/s, p=0.08; comfortable pace: 0.02±0.02 m/s, p=0.5). Subjects with 
shorter stroke-therapy intervals and left-sided lesions showed greater improvement in 
6-min walk velocity (Table 4, Figure 1). Nevertheless, both left- and right-hemisphere 
lesioned subjects walked faster in the 6-min walk test (left-hemisphere lesion: gain in 
velocity 0.16±0.02 m/s, p<0.0001; right-hemisphere lesion: 0.08±0.02 m/s, p<0.001). 
Predictive models explained between 10% and 33% of the variability in therapy 
response (r2 values, Table 4). 
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Discussion 
This post-hoc analysis of two trials on aerobic treadmill exercise demonstrates that 
despite overall significant benefits the response to T-EX varies between individuals. 
Predictors of greater benefit in walking parameters were subcortical and left-sided 
lesion location, smaller lesions and shorter interval time between stroke onset and 
onset of treadmill training. 
Previous studies have demonstrated a relationship between lesion location and size 
and stroke-related deficits or benefits of conventional rehabilitation11-12, 14-15, 27-28. 
While in laboratory animals lesion volume predicts functional deficits27, 29-30, findings 
are heterogeneous in humans. Saunders and colleagues15 reported that for MCA 
territory infarctions, lesion volume is a prognostic outcome indicator. Other studies 
failed to show this relationship16, 31. Chen et al.12 reported critical lesion sizes for 
different brain areas: motor impairment was high when lesions were larger than 
75 cm3 for cortex, 4 cm3 for corona radiata, 0.75 cm3 for internal capsule, 22 cm3 for 
putamen and 12 cm3 for thalamus. This indicates that functional outcome depends 
not only on lesion size but on a combination of lesion size and location. Dawes and 
coworkers31 reported a trend for a correlation between corticospinal tract lesion 
volume and the walking performance after a partial body weight support treadmill 
training. Beloosesky and co-workers11 reported a correlation between lesion size and 
rehabilitation success for cortical infarcts. In our dataset, lesion volume was an 
independent predictor in relative gains in 10-m walk gait velocity (independent of 
baseline deficit). For absolute improvement, lesion location (subcortical vs. cortical), 
was an independent predictor representing the same association as the association 
between lesion volume and relative gain, because cortical strokes were substantially 
larger then subcortical strokes. While patients with subcortical strokes showed 
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significant improvements in 10-m walk, patients with cortical strokes failed to achieve 
significant effects. We also found an association between improvement in gait 
velocity during the 6-min walk (absolute gain) and lesioned hemisphere. Subjects 
with left-sided lesions improved in gait velocity twice as much as those with right-
sided ones, however, both subgroups benefit significantly. While it has been shown 
that overall stroke outcomes at 3-months post-stroke (modified Rankin scale) were 
similar between left and right-sided lesions 32, locomotion was reported to recover 
better in patients with recent (mean 52 days) left-hemisphere lesions using 
conventional rehabilitation techniques 33. This difference may be related to 
visuospatial or attention deficits that are more prominent in subjects with right-
hemisphere infarction and interfere with locomotion. These cognitive functions are 
required for locomotion 34. It is plausible that 6-min walks have higher cognitive 
demands, e.g., higher demands for navigation in space, than 10-m walks and might 
be therefore more sensitive to right-hemisphere damage. 
Age has been reported to predict poor response to CIMT 35, but age was unrelated to 
the benefits conveyed by treadmill therapy here. Similarly, Luk and coworkers 36 
found in 878 stroke survivors that if corrected for disability before the stroke, age per 
se does not predict functional independence at the time of discharge from the 
rehabilitation hospital. In the healthy elderly population, King and coworkers report 
younger age, better health and physical function at baseline to be predictors of 
exercise benefits 37. The reason for not observing predictive effects of age here, 
especially on fitness gains, may be the smaller age span and younger mean age in 
our subject sample as compared with the study by King et al. 
A longer time interval between stroke onset and beginning of treadmill therapy were 
associated with less improvement in gait velocity measured during the 6-min walk 
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(absolute and relative). It is noteworthy that this relationship does not reflect 
differences in the efficacy of interventions delivered in the acute versus the chronic 
period after stroke, because both trials recruited chronic subjects longer than 6 
months after their stroke. While not qualifying the finding that training on treadmill can 
improve walking even long after stroke, this observation stresses the need for 
continued rehabilitation beyond the commonly prescribed 3-6 weeks. 
It has been reported that, apart from lesion-related parameters, more severe 
neurological deficits predicted less improvement after therapy for the recovery of arm 
function 38. A similar finding was reported for constraint-induced movement therapy 
(CIMT) 20. Here we did not find an association between baseline deficits and therapy 
response, that is, there was no effect of a baseline functional measure on its absolute 
change after therapy. However, certain predictors of response also predicted 
baseline function, i.e., lesion volume for 10-m walk velocity. Their predictive value 
may therefore be explained via their effect on baseline function. Subjects in the 
Germany trial had higher fitness levels at baseline than USA participants and showed 
greater improvements, but baseline fitness itself did not predict gains in fitness 
regarding the whole study sample. Thus, the effects on fitness gains are most likely 
not explained by the differences in baseline values between trials, particularly as one 
would likely expect even greater benefits in a less trained (unfit) patient sample. The 
effects might rather be explained by higher training intensity in the Germany trial 
(mean HRR at the end of training: 76% for Germany, 58% for USA). Apart from that, 
none of the investigated independent variables (age, gender, baseline walking, 
stroke-therapy interval, lesion volume, side and location (cortical, subcortical)) 
seemed to predict gains in cardiovascular fitness in our study sample. 
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Despite identifying significant predictors here, at most, predictive models explained 
33% (for 6-min walk velocity) of the variability of therapy effects. Other parameters, 
such as the degree of microvascular encephalopathy, brain atrophy or mental factors 
as motivation and ambition to achieve the training goals, were not evaluated here but 
may be important for predicting the response to treadmill exercise. 
The limitation of this study is the combination of two trials that were conducted in 
different populations and used different durations and intensities of T-EX. As it is 
difficult to recruit large numbers of chronically disabled stroke survivors for prolonged 
training within a research study, we decided to pool the data despite these design 
differences. Trial (USA, Germany) was a covariate in all analyses and interaction 
terms were tested to identify differences between the data sets. As discussed above, 
the effect of trial was significant only in models predicting fitness gains. This may 
have been a confound precluding an identification of predictors of fitness gains. 
Conclusion 
In summary, the present study provides further support for the efficacy of aerobic 
treadmill training in chronic stroke survivors. Walking benefits might be related to 
lesion characteristics with subjects with large and those with right-sided lesions 
improving least. Additionally, earlier timing of the intervention after the stroke may 
optimize treatment effects. These findings might be important to consider, when 
prescribing exercise interventions after stroke, but require further confirmation by 
randomized controlled trials.   
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Table 1. Demographic and baseline characteristics 
 
 All 
(n=52) 
USA 
(n=20) 
Germany 
 (n=32) 
PDifference USA vs. 
Germany trials 
Age, mean(SEM), yrs 66.8 (1.1) 64.0 (2.1) 68.6 (1.1) 0.055 
Gender     
     female, no., (%) 18 (34.62) 12 (60) 6 (18.75) 0.036* 
Stroke-therapy interval,     
mean (SEM), months 
59.00  
(9.28) 
60.06  
(20.01) 
58.34  
(8.77) 
0.93 
Stroke location, no. (%)     
     Brainstem 8 (15.38) 6 (30) 2 (6.24)  
     Cortex 20 (38.46) 5 (25) 15 (46.88)  
     Subcortical 24 (46.15) 9 (45) 15 (46.88)  
Right-sided stroke, no. (%) 20 (38.46) 8 (40) 12 (37.5) 0.86 
Lesion volume (SEM) 4761.16  
(1024.67) 
3007.00 
(1214.68) 
5892.87  
(1472.12) 
0.13 
NIHSS, mean(SEM) 4.08 (0.35) 3.67 (0.53) 4.31 (0.47) 0.39 
NIHSS = National Institutes of Health Stroke Scale 
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Table 2. Baseline and absolute (absCh) and relative changes (relCh) in gait 
performance and fitness 
 
 
 
All 
(n=52) 
 
Baseline absCh relCh 
6-min walk velocity (m/s), 
mean (SEM) 
0.704 
(0.054) 
0.127 
(0.015) 
6-min walk distance (m), 
mean (SEM) 
253.25 
(19.38) 
45.90 
(5.31) 
0.198 
(0.023) 
10-m walk velocity (m/s), 
SSWS, mean (SEM) 
0.672 
(0.048) 
0.059 
(0.015) 
0.133 
(0.035) 
10-m walk velocity (m/s), 
FCWS, mean (SEM) 
0.852 
(0.063) 
0.100 
(0.019) 
0.156 
(0.035) 
Peak VO2 (ml/kg/min), 
mean (SEM) 
17.856 
(0.944) 
3.957 
(0.527) 
0.232 
(0.030) 
 
 
 
 
 
USA 
(n=20) 
Germany 
 (n=32) 
 Baseline absCh relCh  Baseline absCh relCh 
6-min walk velocity (m/s), 
mean (SEM) 
0.585 
(0.061) 
0.115 
(0.024) 
0.778 
(0.077) 
0.135 
(0.019) 
6-min walk distance (m), 
mean (SEM) 
210.6 
(21.82) 
41.35 
(8.65) 
0.206 
(0.046) 279.91 
(27.61) 
48.75 
(6.79) 
0.194 
(0.024) 
10-m walk velocity (m/s), 
SSWS, mean (SEM) 
0.558* 
(0.057) 
0.075 
(0.030) 
0.217 
(0.083) 
0.739* 
(0.067) 
0.0499 
(0.017) 
0.083 
(0.024) 
10-m walk velocity (m/s), 
FCWS, mean (SEM) 
0.748 
(0.083) 
0.126 
(0.036) 
0.25 
(0.084) 
0.914 
(0.087) 
0.084 
(0.019) 
0.100 
(0.022) 
Peak VO2 (ml/kg/min), 
mean (SEM) 
14.125* 
(1.214) 
2.089* 
(0.510) 
0.161 
(0.039) 
20.188* 
(1.167) 
5.066* 
(0.720) 
0.274 
(0.041) 
 SSWS=self-selected walking speed, FCWS=fast comfortable walking speed 
*indicates significant differences between trials (p<0.05) 
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Table 3. Predictors of baseline walking impairment and fitness 
 
Dependent variable predictors mean SEM r p 
10-m walk velocity (m/s), 
comfortable 
trial (USA) 0.56 0.06  0.009 
 trial (Germany) 0.74 0.07   
 NIHSS   -0.54 <0.0001 
10-m walk velocity (m/s), 
fastest 
trial (USA) 0.75 0.09  0.036 
 trial (Germany) 0.91 0.09   
 gender (female) 0.69 0.07  0.032 
 gender (male) 0.93 0.08   
 age   -0.1 0.012 
 lesion volume   -0.4 0.023 
 NIHSS   -0.5 0.005 
6-min walk velocity (m/s) gender (female) 0.56 0.06  0.009 
 gender (male) 0.77 0.07   
 NIHSS (USA)   -0.14 <0.0001 
 NIHSS (Germany)   -0.69  
peak VO2 (ml/kg/min) trial (USA) 14.1 1.21  0.013 
 trial (Germany) 20.2 1.17   
 gender (female) 13.2 1.2  0.0004 
 gender (male) 20.3 1.1   
 stroke side (left) 19.7 1.2  0.009 
 stroke side (right) 14.9 1.4   
 NIHSS   -0.28 0.003 
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Table 4. Predictors of therapy response 
 
Dependent variable predictors mean SEM r p r2overall 
Localization 
(cortical) 
0.015 0.021  0.014 0.12 Absolute gain in 10-m 
walk velocity (m/s), 
comfortable Localization 
(subcortical) 
0.091 0.020    
Lesion volume   -0.24 0.0023 0.32 Relative gain in 10-m 
walk velocity (m/s), 
comfortable 
      
Localization 
(cortical) 
0.047 0.025  0.018 0.11 Absolute gain in 10-m 
walk velocity (m/s), 
fastest Localization 
(subcortical) 
0.134 0.023    
Lesion volume   -0.24 0.0035 0.27 Relative gain in 10-m 
walk velocity (m/s), 
fastest 
Stroke side (left) 0.16 0.02  0.035 0.33 
Stroke side (right) 0.08 0.02    
Absolute gain in 6-
min walk velocity 
(m/s) Stroke-therapy 
interval 
  -0.36 0.0088  
Relative gain in 6-min 
walk velocity (m/s) 
Stroke-therapy 
interval 
  -0.31 0.017 0.1 
Trial (USA) 2.09 0.51  0.005 0.15 Absolute gain in peak 
VO2 (ml/kg/min) Trial (Germany) 5.07 0.72    
Trial (USA) 0.16 0.04  0.0312 0.15 Relative gain in peak 
VO2 (ml/kg/min) Trial (Germany) 0.27 0.04    
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Figure Legend 
Figure 1. The absolute improvement in 6-min walk velocity after treadmill exercise is 
greater in subjects that were trained earlier after the stroke. 
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